Preclinical study of a DNA vaccine targeting SARS-CoV-2

Preclinical study of a DNA vaccine targeting SARS-CoV-2

To fight against the worldwide COVID-19 pandemic, the development of an effective and safe vaccine against SARS-CoV-2 is required. As potential pandemic vaccines, DNA/RNA vaccines, viral vector vaccines and protein-based vaccines have been rapidly developed to prevent pandemic spread worldwide. In t...

Full description

Bibliographic Details
Main Authors: Amaishi, Y. (Author), Arase, H. (Author), Chono, H. (Author), Ehara, T. (Author), Hayashi, H. (Author), Ide, R. (Author), Ju, N. (Author), Kawabata, S. (Author), Komatsuno, T. (Author), Kubota-Koketsu, R. (Author), Matsuura, Y. (Author), Mineno, J. (Author), Morishita, R. (Author), Nakagami, H. (Author), Nakamaru, R. (Author), Okamoto, S. (Author), Ono, C. (Author), Otera, T. (Author), Rakugi, H. (Author), Saito, Y. (Author), Sakaguchi, M. (Author), Shimamura, M. (Author), Shioda, T. (Author), Sun, J. (Author), Tenma, A. (Author), Tomioka, H. (Author), Yanagida, Y. (Author), Yoshida, S. (Author)
Format: Article
Language:English
Published: Elsevier Masson s.r.l. 2022
Subjects:
Adjuvant
Antibody
COVID-19
DNA vaccine
Neutralization activity
T cell activation
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items